Advertisement
Canada markets close in 4 hours 1 minute
  • S&P/TSX

    22,192.31
    +85.23 (+0.39%)
     
  • S&P 500

    5,254.79
    +6.30 (+0.12%)
     
  • DOW

    39,782.74
    +22.66 (+0.06%)
     
  • CAD/USD

    0.7390
    +0.0018 (+0.24%)
     
  • CRUDE OIL

    82.57
    +1.22 (+1.50%)
     
  • Bitcoin CAD

    96,546.62
    +3,236.85 (+3.47%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,234.40
    +21.70 (+0.98%)
     
  • RUSSELL 2000

    2,132.11
    +17.76 (+0.84%)
     
  • 10-Yr Bond

    4.1850
    -0.0110 (-0.26%)
     
  • NASDAQ

    16,407.50
    +7.98 (+0.05%)
     
  • VOLATILITY

    12.92
    +0.14 (+1.10%)
     
  • FTSE

    7,965.39
    +33.41 (+0.42%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6839
    +0.0034 (+0.50%)
     

4 Non-Cannabis Stocks That Have Grown 25% in the Past 3 Months

For investors looking for growth opportunities, the temptation might be to look at cannabis stocks, especially when we?ve seen Aurora Cannabis Inc. (TSX:ACB) double in price in just the past few months, and with demand in the industry expected to outpace supply.

However, pot stocks carry considerable risk, and there are shares of other companies that investors can buy that could generate great returns as well. I?m going to highlight four stocks that have seen returns north of 25% in the past three months that are not in the cannabis industry.

Bombardier, Inc. (TSX:BBD.B) has seen its share price rise 29% in just the past three months, and the manufacturer has had a lot of positive momentum since it announced its deal with Airbus, where they would work together to produce CSeries jets. Since that agreement, we?ve already seen a new order come in for the jets.

ADVERTISEMENT

Bombardier also recently announced that it received an order for over 300 new rail cars. The company is certainly showing some reasons for investors to be optimistic, especially if it can continue to build on this recent progress.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has seen even more impressive returns of 45% in the past three months. In just the last month alone, the share price has risen over 30%.

The company recently got a boost when it announced an offering for unsecured senior notes that would be due in 2025, and that the proceeds from that would be used to pay down debt that will be coming due in 2020.

This buys the company some more time and gives it a bit of breathing room in the next few years. Valeant is still a risky buy, but this move could help give the company some flexibility in the short term.

Canada Goose Holdings Inc. (TSX:GOOS)(NYSE:GOOS) was listed on the TSX back in March, and year to date its share price has more than 60%. In just the past three months, it has increased more than 40% on strong Q2 results that saw sales rise 35% year over year, while profits were up 85%.

The company?s high-end apparel has helped Canada Goose achieve gross margins of over 50%, but the disadvantage is that the high prices might limit the potential growth the company might be able to achieve. However, so far the results speak for themselves, and if Canada Goose can continue to build on its recent performance, then the stock will continue to climb.

Stars Group Inc. (TSX:TSGI)(NASDAQ:TSG) saw its share price dip in September, but since then the stock has risen almost 50% after the company announced that it was raising its guidance for 2017. The company, known for its PokerStars brand, has been diversifying its business and trying to be less reliant on poker for growth.

The stock could see a lot of growth, as the company?s strong cash flow will allow Stars Group to be flexible in its pursuit of expanding both its products and the locations that it operates out of. As online entertainment and gambling continues to grow, there are many good reasons to consider investing in Stars Group.

More reading

Fool contributor David Jagielski has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.